Judge tells FTC and Impax to connect witness testimony to exhibits
The Federal Trade Commission’s administrative law judge on Thursday declined to rule on whether some exhibits were admissible during a pretrial hearing between the agency and generic drugmaker Impax Laboratories, who is accused for participating in a pay-for-delay scheme with brand name drug company Endo.
Subscribe to Global Competition Review
Subscribe and start reading now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10